| About | Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). |
| How we share on the AMR Register | To obtain Paratek’s AMR surveillance data for analysis, researchers should use the AMR Register platform to submit a request. The anonymized data will then be made available to the researcher to download. Data for ongoing surveillance programs will be updated annually. |
| Programs listed for sharing | Organization name AMR surveillance data available on the AMR Register:
|
| What information will be provided | Where available, the following data and information is provided for each dataset:
|
| Data Request Review Process | Researchers can request access to our datasets by completing a data request form on the AMR register. The datasets can be downloaded.
Pursuant to the US DOJ Final Rule – Preventing Access to Americans’ Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern (28 CRF Part 202)
|
| Questions or enquiries |
Please send any questions or enquiries to amr@vivli.org |
| Paratek’s Register or Website |
http://paratek-keystone.com |